Mycoplasma Testing Guide USP 63

Learn mycoplasma testing USP 63 rules, key differences, and compliance tips for pharmaceutical quality control.

SP 63 Mycoplasma Tests in Pharmaceuticals

Mycoplasma contamination remains a critical concern in biopharmaceutical manufacturing. With the introduction of USP 63, the industry now has a standardized framework for Mycoplasma Tests in Pharmaceuticals, improving consistency and regulatory alignment across laboratories.

This article breaks down USP 63, compares it with earlier guidelines, and explains what it means for compliance and testing practices.

What is USP 63?

The United States Pharmacopeia introduced USP 63 Mycoplasma Tests to address a long-standing gap in compendial guidance. Previously, manufacturers relied on:

• FDA’s 1993 Points to Consider (PTC)
• European Pharmacopoeia (EP) Chapter 2.6.7

USP 63 consolidates and harmonizes these approaches, offering a clearer and more standardized method for detecting mycoplasma contamination in pharmaceutical products.

Why USP 63 Matters

For companies performing mycoplasma testing as part of lot release, compliance with USP 63 is essential. Once implemented, it becomes a compendial method, meaning:

• No full validation is required
• Only method verification (USP <1226>) is needed
• Greater regulatory consistency across regions

Key Differences: USP 63 vs EP 2.6.7 vs PTC

While USP 63 closely mirrors EP 2.6.7, some important differences affect testing protocols.

1. Nutritive Properties of Media

Growth media must support mycoplasma detection effectively.

• USP 63: Requires colony counts within a tighter 0.5-log range
• EP 2.6.7: Allows a broader variation (up to 5-fold difference)

👉 Impact: USP 63 is more stringent, requiring more precise media performance.

2. Inhibitory Substances

Test samples may contain substances that suppress mycoplasma growth.

• USP 63: Strict 0.5-log acceptance range
• EP 2.6.7: Less restrictive threshold

👉 Impact: USP 63 reduces the risk of false negatives, improving test reliability.

3. Incubation Conditions

• USP 63 & PTC: 36 ± 1°C
• EP 2.6.7: 35–38°C

Atmosphere differences also exist, particularly in defining microaerophilic conditions.

👉 Impact: Minor differences, but labs must standardize conditions carefully.

4. Positive Controls

• USP 63: Requires at least two mycoplasma strains
• EP 2.6.7: Requires at least one strain

👉 Impact: USP 63 ensures broader detection capability.

Alternative Methods: PCR and Rapid Testing

USP 63 allows nucleic acid-based methods (like PCR), provided they are:

• Validated
• Comparable to traditional culture methods

Modern rapid tests offer:

• Higher sensitivity
• Faster turnaround than the traditional 28-day culture method

However, regulatory expectations for validation are still largely guided by FDA and EP frameworks.

Compliance Requirements for Laboratories

To align with USP 63, laboratories must:

• Update protocols to meet stricter criteria
• Verify methods for each sample matrix
• Ensure media and controls meet new acceptance limits

These adjustments are essential for maintaining compliance across FDA, USP, and EP standards.

Summary

USP 63 marks a major step forward in standardizing Mycoplasma Tests in Pharmaceuticals. While largely aligned with EP 2.6.7, it introduces stricter requirements for:

• Media performance
• Detection sensitivity
• Control usage

For laboratories, adapting to USP 63 ensures improved reliability, regulatory compliance, and product safety.

FAQs: USP 63 Mycoplasma Testing

1. What is USP 63?

USP 63 is a pharmacopeial chapter that standardizes mycoplasma testing in pharmaceuticals.

2. Why are Mycoplasma Tests important in pharmaceuticals?

They detect contamination that can compromise product safety and efficacy.

3. How is USP 63 different from EP 2.6.7?

USP 63 has stricter acceptance criteria, especially for media performance and inhibitory substances.

4. Does USP 63 require method validation?

No, only method verification is required since it is a compendial method.

5. What are inhibitory substances in testing?

They are compounds in samples that can suppress mycoplasma growth and cause false negatives.

6. What incubation temperature is used in USP 63?

36 ± 1°C is recommended for test cultures.

7. Can PCR methods be used under USP 63?

Yes, if validated and proven comparable to culture-based methods.

8. How many positive controls are required?

At least two mycoplasma strains must be used.

9. What is the duration of traditional mycoplasma testing?

Up to 28 days using culture methods.

10. Who must comply with USP 63?

Biopharmaceutical companies conducting mycoplasma testing for product release.